All News

Performance BASDAI & ASDAS in evaluating PsA axial symptoms? 400+ pts DISCOVER 1&2 Weak correlations w/ peripheral arthritis Moderate/strong correlations w/ fatigue & pain Both perform similarly but do they perform well enough? https://t.co/alnrEXtydp Abs#1037 #ACR22 @Rheumnow https://t.co/Zuf1FruneK

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Benefits with receiving anabolic agents upfront before antiresoprtives (as opposed to other way around). Shame about lack of access to this sequence currently @RheumNow #ACR22 #osteoporosis https://t.co/S2ttbrVaab
Julian Segan JulianSegan ( View Tweet)
Low likelihood of syndesmophyte formation in PsA but is more likely assoc'd w/ axial involvement radiographically + high CRP. Abs 1014 #ACR22 @RheumNow https://t.co/M5Tc0fd64s https://t.co/e25gwVQKeo

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
DISCOVER 1 & 2: Subanalysis of GUS in 181 pts w/ Axial PsA and imaging confirmed SI GUS improves BASDAI, mBASDAI, spinal pain, morning stiffness, and ASDAS from W8 to W24 W24 Response rates BASDAI50 38% BASDAI70 20% https://t.co/MrS8atrIOI Abs#1035 #ACR22 @Rheumnow https://t.co/wMDkO1Qak9

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Most important point from the Great Debate on treating pre-RA. Are we really treating to prevent RA or are we simply delaying RA onset? I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs. What would you do? @RheumNow #ACR22

Robert B Chao, MD doctorRBC ( View Tweet)

The Great Debate! Should you treat pre-clinical RA? ACPA+ ~40% did not convert to clinical RA RF+/ACPA+ least likely to seroconvert to negative @RheumNow #ACR22 https://t.co/djVPKDdWjz
Robert B Chao, MD doctorRBC ( View Tweet)
Dr. Talabi: Progestin-only has⬇️thrombotic risk vs. estrogen👇 ‼️Safety signal for DMPA/depo shot bec. might be more prothrombotic vs. other progestin methods; addt'l studies needed; recommend to avoid in aPL+ for now #ACR22 @Rheumnow https://t.co/pQe5H8wqvi
sheila RHEUMarampa ( View Tweet)
"Less than 1 in 6 rheumatology guideline recommendations are informed by head-to-head RCTs." #ACR22 abst#1284 @rheumnow Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines https://t.co/l5NzzcHRSA

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the thoracic spinous processes & Achilles tendon. MEI & MASES best capturing axSpA enthesitis. MEI & SPARCC best in pSpA & PsA. Abs 1004 #ACR22 @RheumNow https://t.co/6IbusqHI5d https://t.co/5y5NFthyJz

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Tofacitinib in new-onset PMR: Nice mechanistic data - all the right things line up - leading to promising proof-of-concept study (EAST PMR) Plenty to tease apart here but real promise to explore in bigger studies ABST1107 #ACR22 @RheumNow https://t.co/s4ts7lrVtZ
David Liew drdavidliew ( View Tweet)
Dr Iyer shares how ROSCE can teach trainees #telerheumatology using video visits: ☝️ Relevant to career, enhanced self-directed learning ☝️Accdg to ROSCE results, improvement needed on telemed focused exams 🤓Video ROSCE as T-L strat, eval #ACR22 @RheumNow #MedEd @rheumarhyme https://t.co/kZXMrbwtzW
sheila RHEUMarampa ( View Tweet)
Coming off denosumab is very tricky! No such thing as drug holiday given high risk of rebound fractures. Need to cap with BP but duration uncertain. @RheumNow #ACR22 #osteoporosis https://t.co/a4VNAI2D49
Julian Segan JulianSegan ( View Tweet)
Was my pleasure to chat with Prof Eder @lihi_eder about her fantastic abstract #1007 about dietary interventions in PsA- DIPSA study! Catch our interview now on below link 🌟 #ACR22 @RheumNow https://t.co/liwc38wErT

Patricia Harkins DrTrishHarkins ( View Tweet)

Abs 1008 at #ACR22 shows endothelial dysfunction found in SpA pts assoc'd with worsening mSASSS, time of disease evolution, BASMI and BASFI, and CV plaques in axSpA. @RheumNow https://t.co/7Zxl4PcPfR https://t.co/3cAqigHtNU

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
The great debate Pre-RA to treat or not to treat? @HaniElgabalawy @Janetbirdope What a conversation with a patient at-risk of RA would look like based on current literature. Would you suggest to treat? If I was Mr Jones, I wouldn’t buy it. #ACRdebate #ACR22 @RheumNow https://t.co/vEj4KOauzz
Aurelie Najm AurelieRheumo ( View Tweet)
Abstr #1037 evaluated BASDAI vs ASDAS in PsA w/ axial dx Both ASDAS & BASDAI showed - strong correlation w/ pt pain & Global Assessment - weak correlation in tender and swollen joint counts and enthesitis #ACR22 @RheumNow #axSpA #PsA https://t.co/EunXIwzn3M
Akhil Sood MD AkhilSoodMD ( View Tweet)
The Great Debate! Should you treat pre-clinical RA? US erosions in 5th MTPs predict clinical arthritis in +CCP "Pre-RA" patients ~15% of patients will develop RA @RheumNow #ACR22 https://t.co/jS2YMlF4iO
Robert B Chao, MD doctorRBC ( View Tweet)
Danish registry, 11000+ pts w/ sarcoidosis: > incidence young males > IR if born after 1976 in males IRR 1.22, no diff in females 1976 = yr systematic BCG vaccination stopped Attributed to ↘️ intake BCG vax Underlying mechanism? https://t.co/At3dUwIgES Abs#1111 #ACR22 @Rheumnow https://t.co/gArfdAVapD

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
The Great Debate! Should you treat pre-clinical RA? "The more good factors you have, the less likely you will develop RA" - Janet Pope Never smoker, normal BMI, low EtOH, exercise, healthy diet @RheumNow #ACR22 https://t.co/jIMOn8ht6u
Robert B Chao, MD doctorRBC ( View Tweet)
70% of #AOSD pts were females! Large HCA database study - incidence rate - 0.16 - 0.21 per 100,000 (similar to French studies). 24% required ICU level of care, 12% had PNA (fig) Mortality is higher than other cohorts - 3.2% #ACR22 @RheumNow abst#0829 https://t.co/fcFUnExYOE
Bella Mehta bella_mehta ( View Tweet)
×